Taken together, our studies suggest that inducing antigens in tumor cells in situ by nucleolin-targeted downregulation of TAP could be as if not more effective than vaccinating against endogenous neoantigens, clinically more feasible, and broadly applicable to all cancer patients. This evidence concerns the gene NUCLEOLIN and neoplasm.